{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:28:55Z","timestamp":1776482935984,"version":"3.51.2"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Merz Center for Quality and Outcomes Research in Dermatologic Surgery"},{"name":"IMPROVED (Measurement of Priority Outcome Variables in Dermatologic Surgery) Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00403-021-02239-6","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T12:02:41Z","timestamp":1621598561000},"page":"357-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Postinflammatory hyperpigmentation: protocol for development of a core outcome set for clinical trials"],"prefix":"10.1007","volume":"314","author":[{"given":"Bianca Y.","family":"Kang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-3251","authenticated-orcid":false,"given":"Sarah A.","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divya","family":"Shokeen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel I.","family":"Schlessinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie J.","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian A.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Sobanko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd V.","family":"Cartee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"2239_CR1","volume-title":"Fitzpatricks dermatol","author":"M Rodrigues","year":"2019","unstructured":"Rodrigues M, Pandya AG (2019) Hypermelanoses. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ et al (eds) Fitzpatricks dermatol, 9th edn. McGraw-Hill Education, New York","edition":"9"},{"key":"2239_CR2","volume-title":"Taylor Kellys dermatol. Skin color","author":"CR Heath","year":"2016","unstructured":"Heath CR, Gathers RC, Taylor SC (2016) Postinflammatory hyperpigmentation\/periorbital hyperpigmentation. In: Kelly AP, Taylor SC, Lim HW, Serrano AMA (eds) Taylor Kellys dermatol. Skin color, 2nd edn. McGraw-Hill Education, New York","edition":"2"},{"key":"2239_CR3","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.jaad.2017.01.035","volume":"77","author":"N Silpa-archa","year":"2017","unstructured":"Silpa-archa N, Kohli I, Chaowattanapanit S, Lim HW, Hamzavi I (2017) Postinflammatory hyperpigmentation: a comprehensive overview. J Am Acad Dermatol 77:591\u2013605. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.035","journal-title":"J Am Acad Dermatol"},{"key":"2239_CR4","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1097\/DSS.0000000000001521","volume":"44","author":"MJ Vanaman Wilson","year":"2018","unstructured":"Vanaman Wilson MJ, Jones IT, Bolton J, Larsen L, Fabi SG (2018) The safety and efficacy of treatment with a 1927-nm diode laser with and without topical Hydroquinone for Facial Hyperpigmentation and Melasma in darker skin types. Dermatol Surg 44:1304\u20131310. https:\/\/doi.org\/10.1097\/DSS.0000000000001521","journal-title":"Dermatol Surg"},{"key":"2239_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/ics.12626","volume":"42","author":"WG Philipp-Dormston","year":"2020","unstructured":"Philipp-Dormston WG, Echag\u00fce AV, Damonte SHP, Riedel J, Filbry A, Warnke K et al (2020) Thiamidol containing treatment regimens in facial hyperpigmentation: an international multi-centre approach consisting of a double-blind, controlled, split-face study and of an open-label, real-world study. Int J Cosmet Sci 42:377\u2013387. https:\/\/doi.org\/10.1111\/ics.12626","journal-title":"Int J Cosmet Sci"},{"key":"2239_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2016.4399","volume":"153","author":"O Agbai","year":"2017","unstructured":"Agbai O, Hamzavi I, Jagdeo J (2017) Laser treatments for postinflammatory hyperpigmentation: a systematic review. JAMA Dermatol 153:199. https:\/\/doi.org\/10.1001\/jamadermatol.2016.4399","journal-title":"JAMA Dermatol"},{"key":"2239_CR7","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1136\/bmj.c365","volume":"340","author":"JJ Kirkham","year":"2010","unstructured":"Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R et al (2010) The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 340:e365. https:\/\/doi.org\/10.1136\/bmj.c365","journal-title":"BMJ"},{"key":"2239_CR8","unstructured":"COMET Initiative | Home n.d. http:\/\/www.comet-initiative.org\/ (accessed Sep 25, 2020)."},{"key":"2239_CR9","unstructured":"Core Outcomes Set Initiative (CS-COUSIN) n.d. \/core-outcomes-set-initiative-csg-cousin (accessed Oct 2, 2020)."},{"key":"2239_CR10","doi-asserted-by":"publisher","unstructured":"Schmitt J, Williams H, HOME Development Group. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol 2010;163: 1166\u20138. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.10054.x","DOI":"10.1111\/j.1365-2133.2010.10054.x"},{"key":"2239_CR11","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/j.1398-9995.2012.02874.x","volume":"67","author":"J Schmitt","year":"2012","unstructured":"Schmitt J, Spuls P, Boers M, Thomas K, Chalmers J, Roekevisch E et al (2012) Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy 67:1111\u20131117. https:\/\/doi.org\/10.1111\/j.1398-9995.2012.02874.x","journal-title":"Allergy"},{"key":"2239_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","volume":"134","author":"J Schmitt","year":"2014","unstructured":"Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S et al (2014) The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol 134:800\u2013807. https:\/\/doi.org\/10.1016\/j.jaci.2014.07.043","journal-title":"J Allergy Clin Immunol"},{"key":"2239_CR13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/bjd.13237","volume":"171","author":"JR Chalmers","year":"2014","unstructured":"Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL et al (2014) Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema\/dermatitis clinical trials (HOME). Br J Dermatol 171:1318\u20131325. https:\/\/doi.org\/10.1111\/bjd.13237","journal-title":"Br J Dermatol"},{"key":"2239_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/jid.2014.320","volume":"135","author":"J Schmitt","year":"2015","unstructured":"Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M et al (2015) The Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological framework to develop core sets of outcome measurements in dermatology. J Invest Dermatol 135:24\u201330. https:\/\/doi.org\/10.1038\/jid.2014.320","journal-title":"J Invest Dermatol"},{"key":"2239_CR15","doi-asserted-by":"publisher","unstructured":"Iyengar S, Williamson PR, Schmitt J, Johannsen L, Maher IA, Sobanko JF, et al. Development of a core outcome set for clinical trials in rosacea: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. Trials 2016;17. https:\/\/doi.org\/10.1186\/s13063-016-1554-3.","DOI":"10.1186\/s13063-016-1554-3"},{"key":"2239_CR16","unstructured":"ImprovedGroup. ImprovedGroup n.d. http:\/\/www.improvedgroup.org (accessed Oct 2, 2020)."},{"key":"2239_CR17","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamadermatol.2019.4212","volume":"156","author":"KA Reynolds","year":"2020","unstructured":"Reynolds KA, Schlessinger DI, Vasic J, Iyengar S, Qaseem Y, Behshad R et al (2020) Core outcome set for actinic keratosis clinical trials. JAMA Dermatol 156:326. https:\/\/doi.org\/10.1001\/jamadermatol.2019.4212","journal-title":"JAMA Dermatol"},{"key":"2239_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16854","author":"T Lange","year":"2020","unstructured":"Lange T, Kottner J, Weberschock T, Hahnel E, Apfelbacher C, Brandstetter S et al (2020) Outcome assessment in dermatology clinical trials and Cochrane reviews: call for a dermatology-specific outcome taxonomy. J Eur Acad Dermatol Venereol JEADV. https:\/\/doi.org\/10.1111\/jdv.16854","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"2239_CR19","unstructured":"COMET Initiative | Outcome classification n.d. http:\/\/www.comet-initiative.org\/Resources\/OutcomeClassification (accessed Oct 2, 2020)."},{"key":"2239_CR20","doi-asserted-by":"publisher","unstructured":"Moza A, Benstoem C, Autschbach R, Stoppe C, Goetzenich A. A core outcome set for all types of cardiac surgery effectiveness trials: a study protocol for an international eDelphi survey to achieve consensus on what to measure and the subsequent selection of measurement instruments. Trials 2015;16. https:\/\/doi.org\/10.1186\/s13063-015-1072-8.","DOI":"10.1186\/s13063-015-1072-8"},{"key":"2239_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G et al (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol. 64:395\u2013400. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.09.012","journal-title":"J Clin Epidemiol."},{"key":"2239_CR22","doi-asserted-by":"publisher","first-page":"e0129514","DOI":"10.1371\/journal.pone.0129514","volume":"10","author":"NL Harman","year":"2015","unstructured":"Harman NL, Bruce IA, Kirkham JJ, Tierney S, Callery P, O\u2019Brien K et al (2015) The importance of integration of stakeholder views in core outcome set development: Otitis media with effusion in children with cleft palate. PLoS ONE 10:e0129514. https:\/\/doi.org\/10.1371\/journal.pone.0129514","journal-title":"PLoS ONE"},{"key":"2239_CR23","doi-asserted-by":"publisher","first-page":"e1002148","DOI":"10.1371\/journal.pmed.1002148","volume":"13","author":"JJ Kirkham","year":"2016","unstructured":"Kirkham JJ, Gorst S, Altman DG, Blazeby JM, Clarke M, Devane D et al (2016) Core outcome set\u2013STAndards for reporting: the COS-STAR statement. PLOS Med 13:e1002148. https:\/\/doi.org\/10.1371\/journal.pmed.1002148","journal-title":"PLOS Med"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-021-02239-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-021-02239-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T13:14:22Z","timestamp":1649682862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-021-02239-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["2239"],"URL":"https:\/\/doi.org\/10.1007\/s00403-021-02239-6","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors has personal or financial relationships with other people or organizations that may influence their interpretation of data or presentation of information. Several of the authors (JFS, TVC, IAN, JJK, KS, and MA) have been involved also in the development of other core outcome sets, and several (JK, JS, and MA) are members of the CS-COUSIN Methods group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval has been given from the Northwestern University Institutional Review Board (IRB) protocol ID: STU00201637.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent will be obtained from all participants prior to enrollment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}